Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
A phase 3 trial of Capivasertib, Docetaxel in prostate cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) is a phase 3 interventional study registered as NCT05348577 by AstraZeneca, with 1035 participants enrolled, started 2022-03-25 and due to reach its primary completion in 2026-03-04. Interventions recorded: capivasertib, docetaxel, placebo. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialCapivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Shares Capivasertib, AstraZeneca.
- TrialCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Shares Capivasertib, AstraZeneca.
- TrialA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
Shares Capivasertib, AstraZeneca.
- TrialPhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti
Shares Docetaxel, AstraZeneca.
- TrialPhase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Shares Docetaxel, AstraZeneca, Prostate cancer.
- TreatmentEstramustine
Shares Docetaxel, Prostate cancer.
- TrialAssess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral
Shares Docetaxel, AstraZeneca.
- TrialCAPItello-281
Shares Capivasertib, Prostate cancer.